The Population Council’s decision to reduce the price of the Dapivirine Vaginal Ring (DVR) by over 54%—from $12.78 to $5.90—marks a transformative moment for HIV prevention. For Zambia, where cost has long constrained access for women and adolescent girls, this development has the potential to expand public sector availability, ease programmatic burdens, and significantly widen prevention choice.
The DVR remains a critical, woman-controlled, long-acting tool offering discreet monthly protection for those aged 16 and above, including breastfeeding mothers. Its relevance is particularly clear for adolescent girls and young women navigating stigma, adherence challenges, and limited negotiating power.
This price shift aligns with Zambia’s HIV Prevention Roadmap and strengthens the foundation for combination prevention alongside oral PrEP, Cabotegravir, and Lenacapavir. The anticipated three-month DVR under review further promises improved adherence and reduced clinic visits.
At Ascend Futures Foundation (AFF), we view this milestone as a catalyst for accelerating equitable access. We remain committed to driving demand creation, supporting national preparedness, and championing community-level access so that prevention becomes a right—not a privilege.
This reduction is more than a global success; it is a win for the African girl, the Zambian woman, and every young person seeking protection that fits their life. It moves Zambia closer to epidemic control and propels our vision of an HIV-free era.
Issued by the Ascend Futures Foundation Management.
10/12/25
